SHMT2 and plasma cell myeloma: Notably, the combination of Len with Serine hydroxymethyltransferase inhibitor 1 (SHIN1)—a small-molecule compound that binds to SHMT2, a subunit of the BRISC complex—further enhances the sensitivity of myeloma cells to Len [139].